Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?

We describe the pattern of potentially targetable genomic alterations in non-ACC salivary gland malignancies according to their frequency rather than to the single non-ACC histotype Expert Opinion/Commentary: The genetic profiling through in-depth molecular analyses [e.g. Next-generation sequencing (NGS)] is advised in all patients affected by recurrent and/or metastatic non-ACC SGCs to find any potentially druggable target. Some histotypes may carry driving mutations (e.g. salivary duct carcinoma and AR expression) that must be investigated and defined. For the rare cancers, access to a referral center is recommended to optimize the management of these patients. PMID: 30897975 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research